Quantcast
Last updated on April 16, 2014 at 17:24 EDT

Latest Applied genetics Stories

2010-10-25 07:30:00

FORT LEE, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Neurologix, Inc. (OTC Bulletin Board: NRGX) today announced that a landmark paper, published on October 20th in Science Translational Medicine demonstrating the importance of the p11 gene in modulating depression in mice, utilized a gene therapy approach to reverse depression in mice for which the Company holds exclusive development rights. Based on the findings reported in the paper, gene therapy may have potential as a new treatment...

2010-10-25 03:39:00

AMSTERDAM, October 25, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT), a leader in the development of gene based therapies, today announced that its gene therapy product incorporating siRNA sequences into microRNA scaffolds to silence Apolipoprotein B100 (AAV-miApoB) was able to significantly lower plasma cholesterol levels in vivo over a period of 18 weeks. These preliminary results suggest that this approach could lead to a treatment...

2010-10-12 17:18:09

 Direct-to-consumer personal genetic profiling services that claim to predict people's health risks by analysing their DNA are often inconclusive and companies that sell them should provide better information about the evidence on which the results are based, says the Nuffield Council on Bioethics, in a new report on the ethics of so-called personalised healthcare services. The report says that claims that these services are leading to a new era of "Ëœpersonalised healthcare'...

2010-10-07 13:43:07

The introduction of a new, fully characterized viral vector for use as reference material to help standardize gene therapy protocols in research applications and human clinical trials is described in an article in Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The article, which is published online ahead of print, is available free online at www.liebertpub.com/hum The growing popularity in the gene therapy community of using recombinant...

2010-10-07 01:00:00

PARIS, Oct. 7 /PRNewswire/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, announces today that Julianne Smith, PhD, head of the Meganuclease Recombination System group at Cellectis genome surgery, will present Cellectis' results at the 18(th) Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) to be held in Milano, Italy, on October 22-25, 2010. Targeted approaches have emerged today as an alternative to current random insertion strategies...

2010-09-24 01:00:00

AMSTERDAM, September 24, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT), a leader in the field of human gene therapy, announced today that the U.S. Food and Drug Administration (FDA) has designated AMT-080, a gene therapy for Duchenne muscular dystrophy (DMD) as an orphan drug. In October 2009, the Committee for Orphan Medical Products of the European Medicines Agency granted AMT-080 orphan designation for the same indication in the...

0e3eb0f689d5bf454af3a5fc0d8032e3
2010-09-01 20:27:15

Researchers clear hurdle on path toward gene-therapy treatment for diseaseOne of the most difficult aspects of working at the nanoscale is actually seeing the object being worked on. Biological structures like viruses, which are smaller than the wavelength of light, are invisible to standard optical microscopes and difficult to capture in their native form with other imaging techniques. A multidisciplinary research group at UCLA has now teamed up to not only visualize a virus but to use...

2010-08-31 00:33:00

AMSTERDAM, The Netherlands, August 31, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2010. Highlights - Glybera(R): - EMA initiated MAA review in 01/2010 - Approval progressing on schedule for decision mid 2011 - Novel biomarker for Glybera(R) activity identified - Hemophilia B: Phase I/II started - Duchenne Muscular...

2010-08-16 18:16:15

In one of only two studies of its kind, a study from researchers at Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts demonstrates that non-viral gene therapy can delay the onset of some forms of eye disease and preserve vision. The team developed nanoparticles to deliver therapeutic genes to the retina and found that treated mice temporarily retained more eyesight than controls. The study, published online in advance of print in Molecular...

2010-08-16 13:19:06

The easy accessibility of the eye and the established link between specific genetic defects and ocular disorders offer hope for using gene therapy to provide long-term therapeutic benefit. Two reports in the current issue of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com), describe the effective replacement of a human gene to preserve photoreceptor function in a mouse model of severe retinal degeneration. The articles are available free...